Industry
Biotechnology
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Loading...
Open
2.84
Mkt cap
878M
Volume
2.9M
High
2.84
P/E Ratio
-1.20
52-wk high
4.16
Low
2.51
Div yield
N/A
52-wk low
1.40
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 2:50 pm
Portfolio Pulse from Avi Kapoor
October 11, 2024 | 2:28 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 8:51 am
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 1:08 pm
Portfolio Pulse from Avi Kapoor
September 10, 2024 | 10:41 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 6:42 pm
Portfolio Pulse from Vandana Singh
August 05, 2024 | 6:27 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.